<DOC>
	<DOC>NCT01715493</DOC>
	<brief_summary>The aim of this study was to assess the effectiveness for small airway inflammation of 4 weeks lysozyme administration in Chronic Obstructive Pulmonary Disease (COPD) and/or asthma.</brief_summary>
	<brief_title>Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Muramidase</mesh_term>
	<criteria>Inclusion criteria: For COPD: Over 20 years of age and below 85 years of age Smoking history Brinkman index 200 or more Diagnosis of COPD Forced expiratory volume in 1 second (FEV1) of &lt;80% of the predicted value Ratio of FEV1 to forced vital capacity (FVC) of &lt;70% symptom of expectorated sputum For Asthma Over 20 years of age and below 85 years of age Scored between 20 to 24 by ACT (Asthma Control Test) Symptom of expectorated sputum Diagnosed partly controlled by global initiative for asthma Exclusion criteria: Egg allergy Domiciliary oxygen therapy Pneumonia or pulmonary tuberculosis Patients with severe cardiovascular disorder, severe kidney disorder, severe hepatic disorder, severe hematological disorder Cancer</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>COPD</keyword>
	<keyword>Asthma</keyword>
	<keyword>Lysozyme Hydrochloride</keyword>
</DOC>